论文部分内容阅读
目的探讨2种光敏剂介导的光动力疗法治疗晚期上消化道肿瘤的临床疗效与安全性。方法回顾性分析鞍山市中心医院2012年1月至2014年10月入院的124例晚期上消化道肿瘤患者,按光敏剂种类分为2组。血卟啉单甲醚组均采用血卟啉单甲醚介导的光动力疗法治疗,血卟啉衍生物组采用血卟啉衍生物介导的光动力疗法治疗,比较2组患者各类型上消化道肿瘤治疗效果评价、治疗前后上消化道梗阻情况与不良反应等。结果血卟啉单甲醚组疾病控制率(91.18%)明显高于血卟啉衍生物组(75.00%),有显著性差异(P<0.05);血卟啉单甲醚组治疗后上消化道梗阻情况组间比较明显优于血卟啉衍生物组,有显著性差异(P<0.05);血卟啉衍生物组患者治疗期间总体不良反应发生率(69.12%)明显高于血卟啉单甲醚组(46.43%),有显著性差异(P<0.05)。结论血卟啉单甲醚介导的光动力疗法治疗晚期上消化道肿瘤的临床疗效更为显著,但存在一定不良反应,应视情况给予权衡。
Objective To investigate the clinical efficacy and safety of two photosensitizer-mediated photodynamic therapy in the treatment of advanced upper gastrointestinal cancer. Methods A retrospective analysis of Anshan Central Hospital from January 2012 to October 2014 in 124 patients with upper gastrointestinal cancer patients, according to the type of photosensitizer is divided into two groups. Hematoporphyrin monomethyl ether group were treated with hematoporphyrin monomethyl ether-mediated photodynamic therapy, hematoporphyrin derivative group using hematoporphyrin derivative-mediated photodynamic therapy, the two groups were compared in all types Gastrointestinal cancer treatment effect evaluation, before and after treatment of upper gastrointestinal obstruction and adverse reactions. Results The hematoporphyrin monomethyl ether group had a significantly higher rate of disease control (91.18%) than that of hematoporphyrin derivative group (75.00%) (P <0.05) (P <0.05). The incidence of adverse reactions (69.12%) in hematoporphyrin derivative group was significantly higher than that in hematoporphyrin group (P <0.05) Monomethyl ether group (46.43%), there was a significant difference (P <0.05). Conclusion Hematoporphyrin monomethyl ether-mediated photodynamic therapy for advanced upper gastrointestinal cancer clinical efficacy is more significant, but there are some adverse reactions, should be given the trade-offs.